815 related articles for article (PubMed ID: 24897131)
1. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
[TBL] [Abstract][Full Text] [Related]
2. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
5. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory bowel disease: current therapeutic options.
Domènech E
Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
[TBL] [Abstract][Full Text] [Related]
7. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome.
Sidhu R; McAlindon ME; Leeds JS; Skilling J; Sanders DS
J Gastrointestin Liver Dis; 2009 Mar; 18(1):23-6. PubMed ID: 19337629
[TBL] [Abstract][Full Text] [Related]
8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
9. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Bansi DS; Chapman RW; Fleming KA
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
13. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease?
Zissis M; Afroudakis A; Galanopoulos G; Palermos L; Boura X; Michopoulos S; Archimandritis A
Am J Gastroenterol; 2001 Jul; 96(7):2177-83. PubMed ID: 11467650
[TBL] [Abstract][Full Text] [Related]
14. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
15. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
von Stein P; Lofberg R; Kuznetsov NV; Gielen AW; Persson JO; Sundberg R; Hellstrom K; Eriksson A; Befrits R; Ost A; von Stein OD
Gastroenterology; 2008 Jun; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
[TBL] [Abstract][Full Text] [Related]
16. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
[TBL] [Abstract][Full Text] [Related]
17. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
[TBL] [Abstract][Full Text] [Related]
18. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
Pedersen N
Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
[TBL] [Abstract][Full Text] [Related]
19. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).
Henriksen M; Jahnsen J; Lygren I; Sauar J; Schulz T; Stray N; Vatn MH; Moum B;
Scand J Gastroenterol; 2006 Sep; 41(9):1037-43. PubMed ID: 16938716
[TBL] [Abstract][Full Text] [Related]
20. Conventional drug therapy for inflammatory bowel disease.
Bryant RV; Brain O; Travis SP
Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
